486 reports of this reaction
2.4% of all POSACONAZOLE DELAYED RELEASE reports
#8 most reported adverse reaction
PRODUCT USE IN UNAPPROVED INDICATION is the #8 most commonly reported adverse reaction for POSACONAZOLE DELAYED RELEASE, manufactured by A2A Integrated Pharmaceuticals. There are 486 FDA adverse event reports linking POSACONAZOLE DELAYED RELEASE to PRODUCT USE IN UNAPPROVED INDICATION. This represents approximately 2.4% of all 20,089 adverse event reports for this drug.
Patients taking POSACONAZOLE DELAYED RELEASE who experience product use in unapproved indication should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT USE IN UNAPPROVED INDICATION is a less commonly reported adverse event for POSACONAZOLE DELAYED RELEASE, but still significant enough to appear in the safety profile.
In addition to product use in unapproved indication, the following adverse reactions have been reported for POSACONAZOLE DELAYED RELEASE:
The following drugs have also been linked to product use in unapproved indication in FDA adverse event reports:
PRODUCT USE IN UNAPPROVED INDICATION has been reported as an adverse event in 486 FDA reports for POSACONAZOLE DELAYED RELEASE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT USE IN UNAPPROVED INDICATION accounts for approximately 2.4% of all adverse event reports for POSACONAZOLE DELAYED RELEASE, making it a notable side effect.
If you experience product use in unapproved indication while taking POSACONAZOLE DELAYED RELEASE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.